Shares of Lifeward Ltd. (NASDAQ:LFWD) plunged 44% after the company announced a heavily discounted public offering that raised investor concerns over dilution.
The medical technology firm, focused on solutions for individuals with mobility impairments, priced a new offering of 4 million ordinary shares at $0.65 each — a steep markdown from its prior trading levels. Alongside the shares, the offering includes warrants giving investors the option to buy an additional 4 million shares at the same $0.65 exercise price.
The company expects to generate approximately $2.6 million in gross proceeds from the sale, excluding placement agent fees and related expenses. Should all warrants be exercised, Lifeward could raise another $2.6 million, though that outcome remains uncertain.
H.C. Wainwright & Co. is managing the transaction as the exclusive placement agent. The offering is anticipated to close around June 26, 2025, contingent on standard closing requirements.
Proceeds from the deal will go toward advancing Lifeward’s commercial initiatives, as well as supporting general corporate operations and working capital needs.
The sharp decline in share price reflects investor reaction to the dilution impact and the discounted terms, both of which add pressure to the company’s short-term valuation.